Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 5/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680130 | 0.88 | ATR (0.38) | ATRRXRARXRBRXRGSCN9A | |
| SCHEMBL680860 | 0.85 | RXRA (0.43) | RXRARXRBRXRGSCN9AMAPK14 | |
| SCHEMBL680086 | 0.82 | RXRA (0.43) | RXRARXRBRXRGSCN9A | |
| SCHEMBL680688 | 0.79 | RXRB (0.44) | RXRARXRBRXRGSCN9AMAPK14 | |
| SCHEMBL679314 | 0.77 | RXRA (0.38) | ATRRXRARXRBRXRGSCN9A | |
| SCHEMBL679898 | 0.76 | RXRA (0.38) | RXRARXRBRXRGSCN9A | |
| SCHEMBL680965 | 0.76 | RXRA (0.40) | RXRARXRBRXRGSCN9AMAPK14 | |
| SCHEMBL679392 | 0.75 | AXL (0.41) | RXRARXRBRXRGMAPK14 | |
| SCHEMBL680423 | 0.74 | EGFR (0.39) | RXRARXRBRXRGSCN9AMAPK14 | |
| SCHEMBL680305 | 0.74 | PLK4 (0.39) | RXRARXRBRXRGSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43878-E1 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2310382-B1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | LILLY CO ELI (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8030302-B2 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2310382-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | Eli Lilly & Company (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010011538-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | MET, MYCBP, MYC | ATR 2993/4885RXRA 4592/4885RXRB 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.